6UKZ
STING C-terminal Domain Complexed with Non-cyclic Dinucleotide Compound 6
6UKZ の概要
エントリーDOI | 10.2210/pdb6ukz/pdb |
分子名称 | fusion protein of Ubiquitin-like protein SMT3 and Stimulator of interferon protein c-terminal domain, 4-[5-(2-{[2-(3-carboxypropanoyl)-4-fluoro-6-methoxy-1-benzothiophen-5-yl]oxy}ethoxy)-6-methoxy-1-benzothiophen-2-yl]-4-oxobutanoic acid (3 entities in total) |
機能のキーワード | agonist, sting (stimulator of interferon genes), transmembrane protein 173 (tmem173), immune system, immune system-inhibitor complex, immune system-agonist complex |
由来する生物種 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) 詳細 |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 69517.68 |
構造登録者 | |
主引用文献 | Pan, B.S.,Perera, S.A.,Piesvaux, J.A.,Presland, J.P.,Schroeder, G.K.,Cumming, J.N.,Trotter, B.W.,Altman, M.D.,Buevich, A.V.,Cash, B.,Cemerski, S.,Chang, W.,Chen, Y.,Dandliker, P.J.,Feng, G.,Haidle, A.,Henderson, T.,Jewell, J.,Kariv, I.,Knemeyer, I.,Kopinja, J.,Lacey, B.M.,Laskey, J.,Lesburg, C.A.,Liang, R.,Long, B.J.,Lu, M.,Ma, Y.,Minnihan, E.C.,O'Donnell, G.,Otte, R.,Price, L.,Rakhilina, L.,Sauvagnat, B.,Sharma, S.,Tyagarajan, S.,Woo, H.,Wyss, D.F.,Xu, S.,Bennett, D.J.,Addona, G.H. An orally available non-nucleotide STING agonist with antitumor activity. Science, 369:-, 2020 Cited by PubMed Abstract: Pharmacological activation of the STING (stimulator of interferon genes)-controlled innate immune pathway is a promising therapeutic strategy for cancer. Here we report the identification of MSA-2, an orally available non-nucleotide human STING agonist. In syngeneic mouse tumor models, subcutaneous and oral MSA-2 regimens were well tolerated and stimulated interferon-β secretion in tumors, induced tumor regression with durable antitumor immunity, and synergized with anti-PD-1 therapy. Experimental and theoretical analyses showed that MSA-2 exists as interconverting monomers and dimers in solution, but only dimers bind and activate STING. This model was validated by using synthetic covalent MSA-2 dimers, which were potent agonists. Cellular potency of MSA-2 increased upon extracellular acidification, which mimics the tumor microenvironment. These properties appear to underpin the favorable activity and tolerability profiles of effective systemic administration of MSA-2. PubMed: 32820094DOI: 10.1126/science.aba6098 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.52 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード